Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Zimmer Biomet Holdings Inc — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.35 (market cap $561.25M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 30.2× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| QCLN | ZBH | |
|---|---|---|
Market Cap | $561.25M | $16.95B |
Volume | 323,550 | 2,505,240 |
Sector | Sector/Thematic | Health |
52-Week High | $68.47 | $103.98 |
52-Week Low | $41.10 | $79.58 |
Typical Hold Time | 50 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $48.35, down 2.2% today, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's performance is heavily influenced by U.S. clean energy policy and geopolitical developments, with recent news highlighting global renewable energy acceleration amid tensions. Support and resistance levels cluster around $50-$52, indicating a key price zone for near-term direction.
The outlook for QCLN hinges on political support for clean energy and rising electricity demand, offering growth potential but facing volatility from policy shifts. Risks include regulatory uncertainty and competitive pressures, while analyst sentiment remains watchful amid evolving market dynamics.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
